3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia
1
Interventions
Methotrexate
9
Cyclophosphamide
9
fludarabine phosphate
7
Vincristine
7
Rituximab
7
Tacrolimus
6
Cytarabine
6
nelarabine
5
Whole-Body Irradiation
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Filgrastim
5
Dexamethasone
5
Antilymphocyte Serum
5
pegaspargase
4
merphos
4
Prednisone
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Calcium Dobesilate
4
tanespimycin
3
dexamethasone acetate
3
dexamethasone 21-phosphate
3
Radiotherapy
3
Lenalidomide
3
Doxorubicin
3
Busulfan
3
Bortezomib
3
prednylidene
2
deltacortene
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
×
Ranitidine
×
Clear all
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts